Amgen Aims To Enter GLP-1 Market With Different Drug Approach

By Maaisha Osman / November 7, 2024 at 9:30 AM

Pharmaceutical company Amgen Inc. says the GLP-1 drug for weight loss it is developing will set itself apart from rival Novo Nordisk and Eli Lilly drugs by addressing the root causes of obesity.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.